Dr. Matthew Stephen Durstenfeld, MD

Dr. Durstenfeld practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Durstenfeld's NPI, 1871903534, was assigned on May 4, 2014. Dr. Durstenfeld graduated from Perelman School of Medicine - Philadelphia in 2014. Dr. Durstenfeld holds California license 154168.

Dr. Durstenfeld's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Durstenfeld's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. Dr. Durstenfeld is also affiliated with UCLA Santa Monica Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Durstenfeld to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Durstenfeld practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Durstenfeld's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Durstenfeld is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Durstenfeld's licenses on file in 2 states: California and New York.

Dmand AI lists atrial fibrillation and flutter, cardiac arrhythmia, chest pain, chest trauma, chronic kidney disease, congestive heart failure, coronary artery disease and heart attack among the conditions Dr. Durstenfeld treats.

CMS data shows 352 Medicare services from Dr. Durstenfeld across 8 procedure codes in 2024, for 240 Medicare patients. Medicare paid $24,338 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 240 Medicare patients who saw Dr. Durstenfeld in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have high blood pressure, and 60% have high cholesterol. 90% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Durstenfeld's median patient age at 58, with 47% women.

In 2024, Dr. Durstenfeld wrote 302 Medicare Part D claims for 66 patients. 75% of them were for generic drugs. CMS names the drug for 151 of them, across 8 drugs with 11 or more claims each, at $17,095 in total drug cost. In 2023, CMS named 87 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Durstenfeld for performance year 2024, reported as part of a group. Dr. Durstenfeld accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 21 papers to Dr. Durstenfeld, published from 2016 to 2025. 2023 was the busiest year, with 4. The most frequent topics are COVID-19, SARS-CoV-2 and Heart Failure. Dr. Durstenfeld has published most often in medRxiv. Dr. Durstenfeld's most frequent co-authors are Michael Joseph Peluso, MD, Steven Grant Deeks, MD and Priscilla Ying Hsue, MD.

Dmand AI links Dr. Durstenfeld to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Post-Acute COVID-19 Syndrome and Post-Infectious Disorders.

CMS Open Payments shows 2 general payments to Dr. Durstenfeld from 2 drug and device companies from 2019 to 2024. Consulting fees make up the largest share, 99% of the total. Merck Sharp & Dohme Corporation paid the most, $3,543.

Dmand AI lists 2 awards for Dr. Durstenfeld, most recently Alan Charney Award for Excellence in Research in 2017.

Dr. Durstenfeld graduated from Perelman School of Medicine - Philadelphia in 2014. Dr. Durstenfeld is a member of ACP and AHA.

Dr. Durstenfeld is in network with 6 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.